BG Medicine (BGMD) stock price, revenue, and financials

BG Medicine market cap is $545.2 k, and annual revenue was $1.57 m in FY 2015
View Company

$545.2 K

BGMD Mkt cap, 05-Feb-2021

$1.6 M

BG Medicine Revenue FY, 2015
BG Medicine Gross profit (FY, 2015)1.1 M
BG Medicine Gross profit margin (FY, 2015), %67.8%
BG Medicine Net income (FY, 2015)-5.3 M
BG Medicine EBIT (FY, 2015)-4.6 M
BG Medicine Cash, 31-Dec-20151.5 M

BG Medicine Revenue

BG Medicine revenue was $1.57 m in FY, 2015

Embed Graph

BG Medicine Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

1.6m2.8m4.1m2.8m1.6m

Cost of goods sold

172.0k841.0k1.2m956.0k505.0k

Gross profit

1.5m2.0m2.8m1.8m1.1m

Gross profit Margin, %

89%70%69%66%68%

Sales and marketing expense

9.5m6.2m2.3m302.0k

R&D expense

8.0m7.6m3.7m2.4m1.8m

General and administrative expense

10.5m7.6m7.1m4.5m3.6m

Operating expense total

18.9m24.7m17.2m9.2m5.7m

EBIT

(17.5m)(22.7m)(14.4m)(7.4m)(4.6m)

EBIT margin, %

(1070%)(807%)(353%)(264%)(296%)

Interest expense

89.0k1.1m

Interest income

31.0k22.0k15.0k2.0k

Net Income

(17.6m)(23.8m)(15.8m)(8.1m)(5.3m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015

Revenue

221.0k179.0k480.0k622.0k641.0k888.0k1.0m1.0m739.0k695.0k437.0k505.0k334.0k

Cost of goods sold

193.0k84.0k147.0k196.0k209.0k280.0k353.0k321.0k248.0k234.0k149.0k172.0k103.0k

Gross profit

28.0k95.0k333.0k426.0k432.0k608.0k653.0k709.0k491.0k461.0k288.0k333.0k231.0k

Gross profit Margin, %

13%53%69%68%67%68%65%69%66%66%66%66%69%

Sales and marketing expense

2.1m1.8m1.4m688.0k647.0k192.0k92.0k4.0k

R&D expense

2.4m1.9m3.0m2.1m2.5m1.4m1.1m1.0m560.0k724.0k483.0k498.0k333.0k

General and administrative expense

2.5m3.1m4.8m4.3m4.4m1.8m2.3m1.6m1.2m1.3m869.0k1.2m920.0k

Operating expense total

4.9m5.0m7.8m6.5m7.0m5.4m5.2m4.1m2.4m2.7m1.5m1.8m1.3m

EBIT

(4.8m)(4.9m)(7.5m)(6.1m)(6.5m)(4.8m)(4.5m)(3.4m)(1.9m)(2.2m)(1.3m)(1.4m)(1.0m)

EBIT margin, %

(2190%)(2745%)(1562%)(979%)(1020%)(541%)(452%)(327%)(263%)(321%)(287%)(286%)(307%)

Interest expense

16.0k153.0k324.0k302.0k289.0k295.0k4.0k

Interest income

24.0k10.0k8.0k9.0k4.0k6.0k3.0k2.0k1.0k

Net Income

(4.8m)(4.9m)(7.7m)(6.4m)(6.8m)(5.4m)(4.8m)(3.7m)(2.2m)(2.4m)(1.3m)(2.0m)(1.0m)

BG Medicine Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Cash

23.9m12.8m7.8m4.1m1.5m

Accounts Receivable

115.0k395.0k319.0k174.0k181.0k

Prepaid Expenses

550.0k558.0k306.0k154.0k100.0k

Inventories

212.0k447.0k459.0k400.0k145.0k

Current Assets

25.3m14.6m8.8m4.9m2.0m

PP&E

301.0k197.0k192.0k117.0k11.0k

Total Assets

26.1m15.2m9.4m5.2m2.1m

Accounts Payable

487.0k1.1m965.0k695.0k558.0k

Short-term debt

3.2m4.4m3.0m

Current Liabilities

5.2m8.3m7.4m4.6m1.2m

Long-term debt

6.6m3.0m

Total Debt

9.9m7.3m3.0m

Total Liabilities

5.2m14.9m10.4m4.7m1.5m

Common Stock

20.0k21.0k28.0k34.0k11.0k

Preferred Stock

2.6m

Additional Paid-in Capital

134.2m137.4m151.8m161.5m164.3m

Retained Earnings

(113.3m)(137.1m)(152.9m)(161.0m)(166.3m)

Total Equity

20.9m309.0k(1.1m)557.0k(2.0m)

Financial Leverage

1.2 x49.3 x-8.7 x9.4 x-1.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015

Cash

18.4m13.1m28.0m22.8m17.6m21.1m16.2m11.3m4.3m9.5m6.3m1.6m178.0k2.6m

Accounts Receivable

76.0k88.0k205.0k198.0k147.0k299.0k402.0k451.0k423.0k353.0k254.0k132.0k255.0k152.0k

Prepaid Expenses

870.0k779.0k891.0k856.0k749.0k806.0k526.0k504.0k644.0k352.0k236.0k249.0k415.0k139.0k

Inventories

234.0k330.0k528.0k308.0k452.0k410.0k269.0k411.0k373.0k554.0k358.0k280.0k300.0k223.0k

Current Assets

33.1m29.2m30.1m24.7m19.4m22.9m17.7m13.0m5.7m10.8m7.2m2.3m1.1m3.2m

PP&E

361.0k348.0k327.0k280.0k239.0k130.0k111.0k194.0k173.0k154.0k135.0k103.0k18.0k14.0k

Total Assets

34.0m30.0m31.1m25.5m20.1m23.5m18.3m13.6m6.2m11.2m7.6m2.6m1.4m3.4m

Accounts Payable

803.0k863.0k1.3m1.0m1.0m1.4m1.7m1.2m773.0k1.0m425.0k579.0k610.0k1.3m

Short-term debt

265.0k1.2m2.2m3.9m3.9m4.3m4.4m4.4m4.1m1.9m1.7m

Current Liabilities

5.1m5.3m7.2m8.3m9.8m9.5m9.2m8.9m7.3m6.4m5.8m3.1m3.6m1.9m

Long-term debt

9.5m8.6m7.6m5.6m5.1m4.1m1.9m745.0k

Total Debt

9.8m9.8m9.8m9.5m9.1m8.4m6.2m5.2m4.1m1.9m1.7m

Total Liabilities

5.1m5.3m16.7m16.9m17.4m15.1m14.3m13.0m9.2m7.3m5.9m3.2m3.7m2.0m

Common Stock

19.0k19.0k20.0k20.0k20.0k28.0k28.0k28.0k28.0k34.0k34.0k34.0k9.0k11.0k

Preferred Stock

2.6m

Additional Paid-in Capital

132.6m133.3m135.4m136.0m136.9m150.9m151.3m151.6m152.0m161.2m161.3m161.7m162.0m164.1m

Retained Earnings

(103.7m)(108.6m)(121.0m)(127.4m)(134.2m)(142.5m)(147.3m)(151.0m)(155.1m)(157.3m)(159.7m)(162.3m)(164.4m)(165.4m)

Total Equity

28.9m24.7m14.4m8.6m2.7m8.4m4.0m610.0k(3.1m)4.0m1.7m(566.0k)(2.4m)(1.3m)

Financial Leverage

1.2 x1.2 x2.2 x3 x7.4 x2.8 x4.6 x22.2 x-2 x2.8 x4.5 x-4.6 x-0.6 x-2.6 x

BG Medicine Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Net Income

(17.7m)(23.8m)(15.8m)(8.1m)(5.3m)

Depreciation and Amortization

420.0k273.0k165.0k131.0k87.0k

Accounts Receivable

671.0k(280.0k)76.0k145.0k(158.0k)

Inventories

(235.0k)(12.0k)59.0k255.0k

Accounts Payable

542.0k802.0k(1.6m)(1.4m)(635.0k)

Cash From Operating Activities

(15.0m)(21.3m)(15.3m)(8.2m)(3.7m)

Purchases of PP&E

(93.0k)(85.0k)(132.0k)

Cash From Investing Activities

(93.0k)(85.0k)(32.0k)13.0k

Long-term Borrowings

(100.0k)(2.5m)(4.5m)(3.0m)

Cash From Financing Activities

36.5m10.3m10.3m4.5m1.1m

Net Change in Cash

21.4m(11.1m)(5.0m)(3.6m)(2.6m)

Interest Paid

2.0k763.0k863.0k506.0k119.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015

Net Income

(8.1m)(13.0m)(7.7m)(14.1m)(20.9m)(5.4m)(10.2m)(13.9m)(2.2m)(4.3m)(6.7m)(1.3m)(3.4m)(4.4m)

Depreciation and Amortization

233.0k330.0k77.0k145.0k210.0k61.0k100.0k236.0k33.0k67.0k100.0k29.0k52.0k69.0k

Accounts Receivable

710.0k698.0k(90.0k)(83.0k)(32.0k)96.0k(7.0k)(56.0k)(104.0k)(34.0k)65.0k42.0k(231.0k)(130.0k)

Inventories

(316.0k)(96.0k)(240.0k)37.0k178.0k36.0k86.0k(95.0k)101.0k120.0k100.0k177.0k

Accounts Payable

300.0k568.0k1.8m2.0m2.6m565.0k275.0k(507.0k)(156.0k)(1.1m)(1.3m)(422.0k)298.0k254.0k

Cash From Operating Activities

(7.2m)(11.2m)(5.7m)(11.0m)(16.5m)(4.2m)(8.8m)(12.8m)(2.4m)(5.0m)(7.1m)(1.4m)(2.2m)(2.5m)

Purchases of PP&E

(8.0k)(65.0k)(82.0k)(82.0k)(85.0k)(115.0k)

Cash From Investing Activities

(12.9m)(14.3m)(82.0k)(82.0k)(85.0k)80.0k80.0k(15.0k)13.0k13.0k

Long-term Borrowings

(100.0k)(100.0k)(333.0k)(666.0k)(1.4m)(1.1m)(2.2m)(3.4m)(1.1m)(2.2m)(3.0m)

Cash From Financing Activities

36.0m36.2m9.9m10.0m10.3m12.5m12.1m11.4m(1.1m)6.8m5.7m(1.1m)(1.7m)1.1m

Net Change in Cash

16.0m10.7m4.1m(1.1m)(6.3m)8.3m3.4m(1.4m)(3.5m)1.8m(1.4m)(2.5m)(3.9m)(1.5m)

Interest Paid

2.0k2.0k62.0k(367.0k)(532.0k)226.0k455.0k673.0k163.0k319.0k433.0k60.0k98.0k81.0k

BG Medicine Ratios

USDQ2, 2011

Financial Leverage

1.2 x

BG Medicine Employee Rating

2.85 votes
Culture & Values
3.5
Work/Life Balance
2.9
Senior Management
1.9
Salary & Benefits
2.8
Career Opportunities
2.2
Source
View BG Medicine profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more